Background. Pathogenicity of donor-specific antibodies (DSAs) can be assessed using the single-antigen flow beads (SAFB) assays through mean fluorescence intensity (MFI) with or without serum ethylenediaminetetraacetic acid (EDTA) treatment, measurement of C1q or C3d binding and/or their intragraft detection [graft-bound donor-specific antibody (gDSA)]. We aimed to investigate which of these markers best associates with antibody-mediated rejection (ABMR) and kidney allograft loss at the time of a for-cause biopsy. Methods. This retrospective, single-centre study included 77 kidney transplant recipients who underwent a for-cause biopsy between December 2004 and July 2013. All displayed serum DSAs were identified on the same day as the biopsy. Sera were tested in parallel with the classical SAFB assay with or without serum EDTA treatment, C1q-and C3d-binding assays. gDSAs were eluted from biopsy fragments and identified with SAFB.
I N T R O D U C T I O N
The single-antigen flow beads (SAFB) assays revolutionized serum immunoglobulin G (IgG) anti-human leukocyte antigen (HLA) antibodies and donor-specific antibodies (sDSA) identification [1] . Kidney recipients with preformed or de novo (dnDSA) sDSA are prone to develop antibody-mediated rejection (ABMR) and allograft loss [2] [3] [4] [5] [6] [7] . However, SAFB-detected sDSA are not undisputedly recognized as reliably supporting clinical decision making [8, 9] . Their prognostic value for risk stratification of allograft loss needs to be determined and for this purpose the following tools can be used (reviewed in Böhmig et al. [10] ).
sDSA strength assessed through SAFB mean fluorescence intensity (MFI) is associated with rejection and graft loss in some [4, 11] but not all studies [12, 13] . Complement interference caused by complement activation on the SAFB surface often leads to underestimating or completely masking strong sDSA [14] [15] [16] [17] [18] , which could explain some discrepancies observed between clinical findings and SAFB assay results. It can easily be overcome by pretreating the serum with ethylenediaminetetraacetic acid (EDTA) [14] [15] [16] [17] [18] .
During ABMR, endothelial cell injury is tightly associated with complement activation. Modified SAFB assays detecting C1q-binding [19] or C3d-activating [20] sDSA detect antibodies present at the highest MFI strengths in the classical IgG SAFB assays [21, 22] . Patients with C1q þ or C3d þ sDSA display more ABMR lesions [23] [24] [25] [26] [27] [28] , but the sensitivity of these assays for predicting ABMR is modest: 50% and 70% for C1q and C3d assays, respectively [22, 29] . Similarly, the ability of these assays for predicting graft loss is unclear: C1q þ DSA was associated with graft loss in some studies [23, 24, 26, 30] but not in others [12, 13, 20, 25, 28, 31, 32] , although C3d þ DSA was associated with lower graft survival in two studies [20, 25] .
Finally, a search for DSA bound to the graft (gDSA for graftbound DSA) could also help stratify graft loss risk. Indeed, we previously reported that gDSA detection was associated with ABMR and poor allograft outcome [33] , yet these results were not confirmed later [34] .
Because the concomitant use of these five SAFB-derived assays in a unique cohort has never been reported, we aimed to determine which assay readouts among sDSA MFI with or without EDTA treatment, sDSA C1q-binding or C3d-activating ability or gDSA positivity would best predict ABMR and kidney allograft survival at the time of a for-cause biopsy.
M A T E R I A L S A N D M E T H O D S

Study design
This retrospective, single-centre study was approved by our institutional review board. Between December 2004 and July 2013, 795 kidney transplant recipients followed at the University Hospital of Bordeaux underwent a needle core for-cause graft biopsy for unexplained serum creatinine or proteinuria increase. We identified sDSA on the same day as the biopsy in 77 (9.7%) of them. For recipients with repeated biopsies, only the first available biopsy/serum pair was considered. Clinical data were obtained from our patient management software (R@N). The study followed the guidelines of the Declarations of Helsinki and Istanbul. Informed consent obtained from each patient was included.
Biopsy elution
Graft biopsies were processed using an acid elution kit (Elukit II; Gamma Biologicals, Houston, TX, USA), as previously described [33] . After mincing and repeated washing, elution was performed with 0.1 mL of glycine solution (0.1 M, pH 2.1) for 10 min at room temperature before centrifugation at 6000 rpm for 2 min. Collected eluates were neutralized using 0.1 mL of tris[hydroxymethyl]-aminomethane solution (1 M, pH 8.5) and stored at À80 C until analysis. When the eluate was positive for HLA antibodies, the supernatant of the last washing step was tested to confirm the selectivity of the process for graft-bound antibodies. All were found to be negative (results not shown).
Antibody testing and HLA typing
IgG anti-HLA class I and class II sDSA was identified using the LabScreen SAFB assays (One Lambda, Canoga Park, CA, USA). Sera were tested with and without EDTA treatment. Complement interference was defined as a minimal MFI increase with EDTA above the intralaboratory SAFB variability, as previously described [16] . The sDSA ability to bind C1q and C3d was evaluated using the C1q Screen (One Lambda) and the C3d-binding (LSA class I and class II C3d-binding assay, Immucor, Norcross, GA, USA) assays, respectively, using the SAFB from the corresponding provider. They were performed by people with expertise in these assays (respectively, J.V. and V.D.). In serum, the positivity threshold was set at a normalized MFI of 500 for IgG and 300 for C1q (baseline formula, HLA Fusion software; One Lambda) and at a background-subtracted MFI of 500 for C3d. Identification of gDSA used the LabScreen SAFB assays with a positivity threshold set at a normalized MFI corresponding to the mean þ 5 SD of the alleles not displayed by the donor and not recognized by a serum antibody, as previously described [33, [35] [36] [37] . When necessary, additional donor HLA typing (HLA-A/B/C/DRB1-3-4-5/DQB1/DQA1/DPB1) was performed on stored DNA using high-resolution reverse SSO-PCR (LabType, One Lambda) or SSP-PCR (SSP, Olerup, Stockholm, Sweden).
Pathology
Biopsies were analysed according to the Banff 2013 classification [38] . C4d staining used indirect immunofluorescence on frozen sections using an anti-human C4d antibody (InGen, Chilly-Mazarin, France).
Statistical analysis
Continuous variables were expressed using means and standard deviations or medians and quartiles/range then compared using Student's t-test or Mann-Whitney U-test when appropriate. Categorical variables were expressed using percentages and compared using the chi-squared test. The ability of sDSA IgG MFI, with or without EDTA treatment, to predict complementbinding/activating ability and gDSA positivity was evaluated using receiver operating characteristics (ROC) with a bootstrapping approach (1000 repeats) in order to determine the confidence intervals of optimal MFI thresholds. ROC area under curve (AUC) comparison was performed with the Hanley and McNeil method. Graft loss was considered as the major event of interest and was censored at the time of patient death. Graft survival was first studied using the Kaplan-Meier method and compared using the log rank test, then a Cox proportional hazard modelling was performed on the entire follow-up period. Associations between phenotypic, histological or immunological factors were explored by univariate analysis. Factors identified as significant were thereafter tested in a multivariate analysis to identify independent risk factors for graft loss. All tests were two-sided and a P-value 0.05 was considered statistically significant. Statistical analyses were performed using JMP version 11.0 (SAS Institute, Cary, NC, USA) and MedCalc (MedCalc Software, Mariakerke, Belgium) software.
R E S U L T S
Description of the study population
The patients' characteristics are summarized in Table 1 . The median sampling time after transplantation was 25 months (range 0.5-251; 25th-75th percentile 2-77). The median duration of postbiopsy follow-up was 36 months (25th-75th percentile 12-54). Acute ABMR was evidenced in 40% of biopsies. Thirty-seven recipients (48%) were treated for ABMR with a combination of corticosteroid pulses, plasma exchange, intravenous immunoglobulin and rituximab. Acute ABMR diagnosis was defined by the concomitant presence of histologic evidence of acute tissue injury (g > 0, ptc > 0, v > 0 and/or thrombotic microangiopathy or acute tubular injury with no other cause), current antibody interaction with vascular endothelium (C4d staining and/or ptcþg!2) and the presence of at least one DSA. If only two of these three features were present, a suspicious acute ABMR diagnosis was made. IL-2, interleukin 2; m-TOR, mammalian target of rapamycin. DSA characteristics for predicting allograft loss HLA-DP (12.3%). EDTA-treated serum MFI was higher for class II than for class I sDSA (median 2291 versus 1085, respectively; P-value < 0.001) (Supplementary data, Table S1 ). Five additional DSA (4 class I and 1 class II) were identified only in Table 2 ). For studying the relationship between sDSA, kidney injury and graft survival, we only considered the sDSA with the highest MFI [immunodominant DSA (iDSA)] (see below).
Performance of C1q, C3d and gDSA assays for ABMR prediction
We explored whether any relation existed between iDSA C1q, C3d and gDSA status and kidney injuries. Microcirculation lesions (ptc þ g ! 2) and transplant glomerulopathy (cg > 0) were significantly more frequent in the C3d þ group (P < 0.01). Biopsy C4d deposition was more frequent in the C1q þ , C3d þ and gDSA þ groups. There was no difference between recipients' groups for the other parameters (Figure 3) . The sensitivity and specificity of C1q, C3d and gDSA assays for predicting ABMR were 68% and 61%, 52% and 70% and 64.5% and 56.5%, respectively ( Table 4 ). The serum iDSA IgG MFI value did not better predict the presence of ABMR, yet the ROC curve AUC was improved after EDTA treatment (AUC ¼ 0.56 and P ¼ 0.38 without EDTA treatment versus AUC ¼ 0.61 and P ¼ 0.09 with EDTA treatment). Similar results were obtained when considering cumulative DSA IgG MFI (MFI sum) (AUC ¼ 0.58 and P ¼ 0.22 without EDTA treatment versus AUC ¼ 0.61 and P ¼ 0.09 with EDTA treatment).
Graft survival according to C1q, C3d and gDSA status and immunodominant sDSA IgG MFI at the time of allograft biopsy During postbiopsy follow-up, 44 (57.1%) recipients lost their graft in a median time of 19 months (range 0-92; 25th-75th percentile 7-49). Death-censored graft survival at 60 months was not different between the C1q þ and C1q À groups ( Figure 4A , P ¼ 0.06) or gDSA þ and gDSA À groups ( Figure 4B ; P ¼ 0.06) but was lower in C3d þ patients ( Figure 4C , P ¼ 0.01). To analyse relationships between sDSA IgG MFI and graft survival, we classified the recipients into quartiles according to iDSA IgG MFI distribution ( Figure 5 ). The 5-year graft survival was significantly lower for recipients with an iDSA MFI with EDTA above the median value, i.e. 3800 (P ¼ 0.01), but not without EDTA (median 2500; P ¼ 0.07).
A similar trend was observed in the EDTA-treated condition when using the MFI sum of DSA instead of the iDSA, although the difference was not significant (P ¼ 0.08 with EDTA, P ¼ 0.41 without EDTA; Supplementary data, Figure S2 ).
Identification of independent factors associated with graft loss at the time of allograft biopsy
At the time of biopsy, univariate analysis identified eight factors associated with graft loss (Table 5) : the estimated glomerular filtration rate (eGFR) using the modification of the diet in renal disease (MDRD) formula, four histologic features (ptc þ g ! 2, cg > 0, ci þ ct score and C4d positivity) and three DSA characteristics (C3d positivity, EDTA iDSA IgG MFI as a continuous variable and EDTA iDSA IgG MFI >3800).
Because the DSA characteristics identified were tightly associated, four multivariate models were built to determine whether any of them could identify an independent factor associated with graft loss. C3d positivity and EDTA iDSA IgG MFI >3800 were tested separately with eGFR and Banff lesions belonging to acute ABMR (ptc þ g ! 2 and C4d staining) or associated with chronic renal injuries (cg > 0 and ci þ ct score). The only independent factors that remained associated with graft loss were eGFR, transplant glomerulopathy and C4d positivity (Table 6 ).
D I S C U S S I O N
DSA analysis at the time of a for-cause biopsy showed the (i) tight association between all five DSA assays assessed in this study; (ii) efficient prediction of C1q and C3d assay results by SAFB serum IgG measurement once complement interference is annihilated; (iii) absence of reliable prediction of ABMR with any of the five DSA features explored; (iv) association sDSA EDTA MFI and the presence of C3d þ sDSA but not C1q þ sDSA or gDSA with graft loss in univariate analysis and (v) loss of this association when adjusted on eGFR, transplant glomerulopathy and C4d positivity. Several groups showed that complement-binding/activating ability of sDSA in SAFB assays tightly relates to IgG assay MFI values [13, 16, 20-22, 25, 26, 29, 30] . Complement interference was quite frequent in our cohort, affecting 17.1% of sDSA and 31.1% of recipients. It induces a more or less profound underestimation of MFI strength and could explain why the first reports exploring C1q-binding antibodies did not describe interdependence between C1q positivity and IgG MFI values, since C1q þ sDSA with very low MFI were described [24, 39] . Of note, this pattern can sometimes also be attributed to IgM interference [18, 40] . Blocking complement interference with EDTA significantly increased the ROC curve AUC of IgG MFI measurement for predicting C1q and C3d assay results compared with to the untreated condition, with similar and very satisfactory sensitivity/specificity in the 90% range. Interestingly, we previously obtained similar results for flow cytometry crossmatch results prediction [41] . The usefulness of the C1q and C3d assays can therefore reasonably be called into question, as their results are reliably predicted by EDTA-treated IgG MFI with a similar threshold, $3800 MFI in this study. Noteworthy is that the reported IgG MFI cutoffs predicting C1q positivity widely fluctuate between reports, reaching up to 14 000 MFI [13, 21, 25, 30] . These discrepancies could be explained by the lack of standardization for both the IgG and complement-binding SAFB assays and also by differences in the size or composition of studied populations. The presence of a gDSA was less efficiently predicted by sDSA IgG MFI, suggesting that gDSA detection could also depend on additional factors, such as the properties of the targeted antigens, e.g. expression density in the kidney or availability for sDSA recognition, and technical considerations, e.g. the size of tissue fragment or biopsy localization [36, 42] . Median IgG MFI sum value with EDTA treatment of sera. HR, hazard ratio; CI, confidence interval; MMF, mycophenolate mofetil; ptc, peritubular capillaritis; g, glomerulitis; cg, transplant glomerulopathy; v, vasculitis; ci, interstitial fibrosis; ct, tubular atrophy; i, interstitial inflammation; t, tubulitis; MFI sum, sum of DSA mean fluorescence intensities. HR, hazard ratio; CI, confidence interval; ptc, peritubular capillaritis; g, glomerulitis; cg, transplant glomerulopathy; ci, interstitial fibrosis; ct, tubular atrophy.
Our cohort was composed of recipients who all displayed sDSA at the time of biopsy, but <50% suffered ABMR at this moment, according to the Banff 2013 criteria. This heterogeneity could be attributed to the various reasons that motivated the biopsy, such as a decrease of renal function or proteinuria discovery. The iDSA positivity for C1q, C3d and gDSA was more frequently associated with biopsy C4d deposition. Microcirculation lesions and glomerulopathy scores were only associated with C3d positivity, yet a trend was reached for C1q and gDSA positivity. The latter results could be explained by a lack of power for this analysis. Nevertheless, our results indicate that they cannot replace the allograft biopsy for ABMR diagnosis, in accordance with previous reports showing that 30-60% of C1q þ or C3d þ patients did not develop ABMR [23, 25, 28] . Moreover, the sensitivity for predicting ABMR is poor: 31-68% versus 52-73% for the C1q and C3d assays, respectively [13, 29] . In addition, nearly 30% of C1q
À patients can develop ABMR [22, 25, 26] and most of them lose their graft because of chronic ABMR, although later [25, 30] .
Since its initial description in 2011 [31, 39, 43] , several reports have explored the usefulness of sDSA C1q-binding ability in identifying patients at higher risk for graft loss [15, 23, 24, 28] . Pretransplant C1q þ sDSA were not associated with graft loss when compared with C1q
À sDSA [12, 32] . In prospective post-transplant cohorts, C1q þ sDSA were associated with graft loss in three studies [23, 24, 30] , but not in two others [25, 28] . In cross-sectional posttransplant studies, C1q þ sDSA was associated with graft loss in one pediatric cohort [26] but not in three adult cohorts [13, 20, 31] . These discrepancies could be attributed to the design of these studies. Most prospective studies analysed sDSA early posttransplant and associated C1q þ sDSA to lower graft survival [23, 24, 30] . In contrast, cross-sectional studies analysed sDSA later, at the time of the biopsy or dnDSA development, and showed identical outcomes between C1q þ and C1q
À DSA, as we find in the present work [13, 20, 31] . We and others previously reported that complement-binding sDSA accelerated ABMR and graft loss, but long-term persistence of noncomplement-binding sDSA led to comparable outcome [25, 30] . Cross-sectional studies often capture the patient when renal dysfunction occurs and could mix C1q þ patients with long-term persistent C1q
À patients, who eventually show a similarly poor outcome [30] .
Univariate analyses showed that iDSA IgG MFI with EDTA treatment and C3d þ DSA positivity were associated with subsequent graft loss. Other factors associated with graft loss largely retrieved in the literature were eGFR, microvascular inflammation, transplant glomerulopathy, interstitial fibrosis/tubular atrophy and C4d positivity [20, 24, [44] [45] [46] . When adjusted on eGFR and on these histologic criteria, neither iDSA IgG MFI with EDTA treatment nor C3d positivity remained associated with graft survival. These data confirm the findings of Wiebe et al. [13] showing that MFI is not an independent factor associated with graft loss at the time of dnDSA development. C3d þ DSA were associated with lower graft survival when analysed prospectively in univariate analysis [25] or at ABMR diagnosis in multivariate analysis [20] . Our results complete this picture by showing that C3d þ DSA were no longer associated with allograft loss in a cohort including patients without ABMR. Transplant glomerulopathy could explain the poorer outcome in C3d À sDSA þ patients. Thus the prognostic value of the C3d assay could be restricted to patients suffering ABMR and not be applicable to all biopsied grafts.
Regarding gDSA, there are now opposite findings regarding their association with graft loss in kidney transplantation [33, 34] . Our present results did not associate gDSA with graft loss. In line with this, it was reported that gDSA can sometimes be evidenced several months before ABMR lesions become detectable, suggesting that gDSA are not always associated with early graft loss once detected [34] .
The main limitation of our study relies on the inclusion criteria. We retrospectively included patients who underwent a for-cause graft biopsy and had a serum DSA detectable the same day of biopsy. Indeed, because in our centre the DSA screening at the time of biopsy was not systematic throughout this period, we could have missed an unknown percentage of patients with DSA. This could have introduced a sampling bias and also explain the rather small number of patients studied. However, our data are concordant with previously published studies [13, 34] and this limit does not impact the results about the predictability of C1q, C3d and gDSA positivity by EDTA MFI.
In conclusion, at the time of a for-cause biopsy, our findings do not plead for systematically implementing any of the C1q, C3d or gDSA assays. Indeed, none of them independently predicted ABMR nor was associated with graft loss, while eGFR and histopathologic criteria of chronic ABMR remained the best prognostic factors for graft loss.
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